PowerShares Dynamic Retail ETF (PMR)
NYSEArca - NYSEArca Delayed Price. Currency in USD
- PR Newswire•14 hours ago
MADRID, October 24, 2016 /PRNewswire/ -- PharmaMar (MCE: PHM) has announced today the opening of a new affiliate in Austria with the aim of reinforcing the presence of the Company within Europe, one of ...
- PR Newswire•6 days ago
PharmaMar (PHM) announces today that the patient recruitment for the randomized and pivotal Phase III "CORAIL" study with lurbinectedin (PM1183), for the treatment of platinum-resistant ovarian cancer, has been successfully completed. As Dr Arturo Soto, Director of the Clinical Department of PharmaMar´s Oncology Business Unit, explains "the study has been completed three months ahead of schedule, which reflects the interest in the drug and in the study and also a necessity by the investigators for a new therapeutic alternative for these patients".
- PR Newswire•14 days agoPharmaMar Announces Positive Results From its Phase II Study With lurbinectedin in BRCA 1/2 - Associated Metastatic Breast Cancer at the ESMO 2016 Congress
MADRID, October 10, 2016 /PRNewswire/ -- The data was presented at an oral session at the European Society of Medical Oncology (abstract #2333) The study meets its primary objective obtaining an overall ...